Increasing evidence suggests that Alzheimer's disease (AD) sufferers show region-specific reductions in cerebral glucose metabolism, as measured by [18F]-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET). We investigated preclinical disease stage by cross-sectionally examining the association between global cognition, verbal and visual memory, and 18F-FDG PET standardized uptake value ratio (SUVR) in 43 healthy control individuals, subsequently focusing on differences between subjective memory complainers and non-memory complainers. The 18F-FDG PET regions of interest investigated include the hippocampus, amygdala, posterior cingulate, superior parietal, entorhinal cortices, frontal cortex, temporal cortex, and inferior parie...
Patients with global amnesia of different aetiologies (n = 11), and patients with probable Alzheimer...
Abstract Simultaneously evaluating resting-state brain glucose metabolism and intrinsic functional ...
BACKGROUND: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...
Increasing evidence suggests that Alzheimer's disease (AD) sufferers show region-specific reductions...
Differences in brain metabolism as measured by FDG-PET in prodromal and early Alzheimer's disease (A...
Objective This study was designed to test the hypothesis that baseline glucose metabolism and med...
BACKGROUND: The recent development of tau-specific positron emission tomography (PET) tracers has al...
Background: Autobiographical memory (AM) changes are the hallmark of Alzheimer's disease (AD) and mi...
Quantitative scalp EEG from 32 channels and the cerebral glucose metabolic rate from the 32 underlyi...
Background: The recent development of tau-specific positron emission tomography (PET) tracers has al...
Purpose The purpose of the study was the identification of group and individual subject patterns ...
Using [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) patients with Alzheimer's di...
International audienceObjective To assess the role of biomarkers of Alzheimer disease (AD), neurodeg...
OBJECTIVE: To identify biological evidence for Alzheimer disease (AD) in individuals with subjective...
Simultaneously evaluating resting-state brain glucose metabolism and intrinsic functional activity h...
Patients with global amnesia of different aetiologies (n = 11), and patients with probable Alzheimer...
Abstract Simultaneously evaluating resting-state brain glucose metabolism and intrinsic functional ...
BACKGROUND: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...
Increasing evidence suggests that Alzheimer's disease (AD) sufferers show region-specific reductions...
Differences in brain metabolism as measured by FDG-PET in prodromal and early Alzheimer's disease (A...
Objective This study was designed to test the hypothesis that baseline glucose metabolism and med...
BACKGROUND: The recent development of tau-specific positron emission tomography (PET) tracers has al...
Background: Autobiographical memory (AM) changes are the hallmark of Alzheimer's disease (AD) and mi...
Quantitative scalp EEG from 32 channels and the cerebral glucose metabolic rate from the 32 underlyi...
Background: The recent development of tau-specific positron emission tomography (PET) tracers has al...
Purpose The purpose of the study was the identification of group and individual subject patterns ...
Using [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) patients with Alzheimer's di...
International audienceObjective To assess the role of biomarkers of Alzheimer disease (AD), neurodeg...
OBJECTIVE: To identify biological evidence for Alzheimer disease (AD) in individuals with subjective...
Simultaneously evaluating resting-state brain glucose metabolism and intrinsic functional activity h...
Patients with global amnesia of different aetiologies (n = 11), and patients with probable Alzheimer...
Abstract Simultaneously evaluating resting-state brain glucose metabolism and intrinsic functional ...
BACKGROUND: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...